Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.70 |
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | RBP4 | P02753 | 1/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265025 | 0.88 | TRPV1 (0.78) | NPSR1HSD17B10TRPV1CA12CA1 | |
| SCHEMBL4262251 | 0.85 | HSD17B10 (0.71) | NPSR1HSD17B10TRPV1CA12CA1 | |
| SCHEMBL4274909 | 0.84 | TRPV1 (0.80) | NPSR1HSD17B10TRPV1CA12CA1 | |
| SCHEMBL4269392 | 0.83 | TRPV1 (0.73) | NPSR1HSD17B10TRPV1CA12CA1 | |
| SCHEMBL4262793 | 0.82 | TRPV1 (0.82) | NPSR1HSD17B10TRPV1CA12CA1 | |
| SCHEMBL3712104 | 0.81 | TRPV1 (0.80) | NPSR1HSD17B10TRPV1CA12CA1 | |
| SCHEMBL6430919 | 0.79 | TRPV1 (0.77) | NPSR1HSD17B10TRPV1CA12CA1 | |
| SCHEMBL4262868 | 0.79 | TRPV1 (0.77) | NPSR1HSD17B10TRPV1CA12CA1 | |
| SCHEMBL4411583 | 0.78 | TRPV1 (0.73) | NPSR1HSD17B10TRPV1CA12CA1 | |
| SCHEMBL16690805 | 0.78 | RBP4 (0.81) | NPSR1HSD17B10TRPV1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | BAKTHAVATCHALAM RAJAGOPAL | 2009-03-26 | — | — | US | disclosed |
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | BAKTHAVATCHALAM RAJAGOPAL | 2009-03-26 | — | — | US | disclosed |
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | BAKTHAVATCHALAM RAJAGOPAL | 2009-03-26 | — | — | US | disclosed |
| EP-1581225-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040142958-A1 | Combination therapy for the treatment of pain | NEUROGEN CORPORATION | 2004-07-22 | — | — | US | disclosed |
| WO-2004054582-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-6723730-B2 | DIARYL PIPERAZINES AND RELATED COMPOUNDS USEFUL IN THE TREATMENT OF A CHRONIC AND ACUTE PAIN CONDITIONS, ITCH AND URINARY INCONTINENCE. | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | TRPV1, TRPA1, TRPV5 | NPSR1 90/4885HSD17B10 3252/4885TRPV1 1/4885 |
| US-20040142958-A1 | Combination therapy for the treatment of pain | OPRK1, OPRL1, OPRM1 | NPSR1 53/4885HSD17B10 3853/4885TRPV1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.